Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Biomarker testing through next generation sequencing (NGS) technology has enabled precision oncology to deliver faster, cheaper, and more accurate tumor data.
The Oral Adherence Toolkit provides strategies and resources that nurses can use to facilitate adherence among patients with cancer.
In August 2021, ONS brought together 17 oncology nurses to discuss their experiences with immuno-oncology, precision oncology, and nurse navigation. The goal was to assess their understanding of and identify gaps related to precision oncology and the role of the nurse navigator. This clinical update summarizes the findings of the focus group proceedings.
This toolkit is a resource for Oncology Nurse Navigators looking to improve patient care coordination.
Positive phrases or statements that challenge negative or unhelpful thoughts can motivate you, encourage positive lifestyle changes, and boost your self-esteem. Repeat self-affirmation mantras regularly to fully reap the benefits of this practice and make long-term changes to the way you think and feel.
You are the oncology nurse caring for Maria, who has been diagnosed with non-small cell lung cancer (NSCLC). She says she doesn’t understand how she developed lung cancer because she has always lived a clean lifestyle according to her religious practices. You notice that although Maria is initially conversant with you, she allows her husband to speak for her whenever he is present. When you mention your observation to Maria, she tells you that in her religious culture, medical decisions are deferred to the high elders of the church.
I often use mnemonics, a memory tool, to simplify learning. Mnemonics can be any pattern of letters, numbers, words, images, or other relatable associations that help you remember.
Patients who take anxiety or depression medication are more likely to obtain prostate-specific antigen (PSA) tests, according to study findings that researchers presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (ZynlontaTM) for adults with relapsed or refractory large B-cell lymphoma.